Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May;55(5):e13227.
doi: 10.1111/cpr.13227. Epub 2022 Apr 11.

Combination of resolvin E1 and lipoxin A4 promotes the resolution of pulpitis by inhibiting NF-κB activation through upregulating sirtuin 7 in dental pulp fibroblasts

Affiliations

Combination of resolvin E1 and lipoxin A4 promotes the resolution of pulpitis by inhibiting NF-κB activation through upregulating sirtuin 7 in dental pulp fibroblasts

Xiaochen Liu et al. Cell Prolif. 2022 May.

Abstract

Objectives: To determine whether the combination of resolvin E1 (RvE1) and lipoxin A4 (LXA4) could promote resolution of pulpitis and to investigate the mechanism.

Materials and methods: Preliminary screening was first conducted in four specialized pro-resolving mediators (SPMs). Real-time quantitative polymerase chain reaction, western blotting, enzyme-linked immunosorbent assay and double-immunofluorescence labelling were employed to assess the expression of RelA, SIRT1, SIRT6, SIRT7 and pro-inflammatory factors. Dental pulp fibroblasts (DPFs) were transfected with siRNA to assess the biological role of SIRT7. A pulpitis model was utilized to evaluate the in vivo curative effect.

Results: Preliminary results showed that RvE1 and LXA4 reduced the expression of RelA more markedly than other two SPMs. Both RvE1 and LXA4 treatment downregulated nuclear factor kappa B (NF-κB) activation and increased the expression of SIRT1, SIRT6 and SIRT7, more so in combination than alone. Double-immunofluorescence labelling showed that SIRT7 co-localized with p-p65 and Ac-p65 in the nucleus. Inhibiting ChemR23 and ALX reversed the expression of RelA mRNA, p-p65 and Ac-p65 proteins, pro-inflammatory factors, SIRT1, SIRT6 and SIRT7. Silencing SIRT7 significantly increased p-p65 and Ac-p65 protein levels and decreased SIRT1 and SIRT6 expression. In vivo experiments showed that combined administration of RvE1 and LXA4 promoted pulpitis markedly to resolution.

Conclusions: Combination of RvE1 and LXA4 effectively inhibited NF-κB activation by upregulating SIRT7 expression in DPFs, leading to reduced production of pro-inflammatory factors and promotion of pulpitis resolution.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

FIGURE 1
FIGURE 1
Effects of combined administration of RvE1 and LXA4 on pro‐inflammatory factor expression. (A) Expression of RelA mRNA in LPS‐induced DPFs after treatment with four representative specialized pro‐resolving mediators. (B) Expression of RelA mRNA in LPS‐induced DPFs after treatment with RvE1 or LXA4 alone, and a combination of RvE1 and LXA4. (C) NLRP3, (D) caspase‐1, (E) IL‐1β and (F) IL‐18 mRNA levels on LPS‐induced DPFs detected by qPCR and (G) their protein levels tested by western blotting (normalized to that of β‐tubulin). (H) IL‐1β and (I) IL‐18 protein levels from cultural supernatant detected by ELISA. Other NF‐κB‐dependent expression of genes (J) IL‐6, (K) TNF‐α, (L) CCL2 and (M) CCL7 detected by qPCR. (*p < 0.05 and **p < 0.01). DPFs, dental pulp fibroblasts; ELISA, enzyme‐linked immunosorbent assay; LPS, lipopolysaccharide; LXA4, lipoxin A4; NF‐κB, nuclear factor kappa B; qPCR, quantitative polymerase chain reaction; RvE1, resolvin E1
FIGURE 2
FIGURE 2
Effects of the RvE1 and LXA4 combination on NF‐κB modification. (A) NAD+/NADH ratio measured by a NAD+/NADH assay kit. (B) SIRT1, (C) SIRT6, and (D) SIRT7 mRNA levels detected by qPCR. (E) Expression of p65 protein in both cytoplasm and nucleus detected by western blotting, normalized to β‐actin (in cytoplasm) or PCNA (in nucleus). (F) Phosphorylation and acetylation levels of p65 and expressions of SIRT1, SIRT6 and SIRT7 protein (normalized to that of β‐tubulin) detected by western blotting. (G) Representative double‐immunofluorescence labelling images of SIRT7 (green) and p‐p65 (red), and the nuclei were stained with DAPI (blue). (H) Representative double‐immunofluorescence labelling images of SIRT7 (green) and Ac‐p65 (red), and the nuclei were stained with DAPI (blue). (*p < 0.05 and **p < 0.01). DAPI, 4′,6‐diamidino‐2‐phenylindole; LXA4, lipoxin A4; NAD+, nicotinamide adenine dinucleotide; NF‐κB, nuclear factor kappa B; qPCR, quantitative polymerase chain reaction; RvE1, resolvin E1
FIGURE 3
FIGURE 3
Pro‐resolving effect of the RvE1 and LXA4 combination after ChemR23 and/or ALX inhibition. (A) Expression of RelA mRNA detected by qPCR. (B) NAD+/NADH ratio measured by an NAD+/NADH assay kit. (C) SIRT1, (D) SIRT6 and (E) SIRT7 mRNA levels detected by qPCR. (F) Expression of p65 protein in both cytoplasm and nucleus detected by western blotting, normalized to β‐actin (in cytoplasm) or PCNA (in nucleus). (G) Phosphorylation and acetylation levels of p65 and expressions of SIRT1, SIRT6 and SIRT7 protein (normalized to β‐tubulin) detected by western blotting. (H) Representative double‐immunofluorescence labelling images of SIRT7 (green) and p‐p65 (red), and the nuclei were stained with DAPI (blue). (I) Representative double‐immunofluorescence labelling images of SIRT7 (green) and Ac‐p65 (red), and the nuclei were stained with DAPI (blue). (*p < 0.05 and **p < 0.01). DAPI, 4′,6‐diamidino‐2‐phenylindole; LXA4, lipoxin A4; NAD+, nicotinamide adenine dinucleotide; qPCR, quantitative polymerase chain reaction; RvE1, resolvin E1
FIGURE 4
FIGURE 4
Pro‐resolving effect of the RvE1 and LXA4 combination after SIRT7 silencing. (A) Silencing efficiency of si‐SIRT7 on mRNA level, and (B) that of in protein level. (C) Expression of RelA mRNA detected by qPCR. (D) NAD+/NADH ratio measured by an NAD+/NADH assay kit. (E) SIRT1 and (F) SIRT6 mRNA levels detected by qPCR. (G) Expression of p65 protein in both cytoplasm and nucleus detected by western blotting, normalized to β‐actin (in cytoplasm) or PCNA (in nucleus). (H) Phosphorylation and acetylation levels of p65 and expressions of SIRT1, SIRT6 and SIRT7 protein (normalized to β‐tubulin) detected by western blotting. (I) Representative double‐immunofluorescence labelling images of p‐p65 (green) and Ac‐p65 (red), and the nuclei were stained with DAPI (blue). (*p < 0.05 and **p < 0.01). DAPI, 4′,6‐diamidino‐2‐phenylindole; LXA4, lipoxin A4; NAD+, nicotinamide adenine dinucleotide; qPCR, quantitative polymerase chain reaction; RvE1, resolvin E1
FIGURE 5
FIGURE 5
Therapeutic effect of combined administration of RvE1 and LXA4 in a rat pulpitis model. (A) Representative haematoxylin–eosin‐stained images on days 1, 3 and 7 after surgery. (B) Representative immunofluorescence images of CD11b on days 1, 3 and 7 after surgery. (C) Representative immunohistochemistry‐stained images of OCN on days 3 and 7 after surgery. (D) Statistical analysis of number of immune cells. (E) Statistical analysis of the area of mineralized tissue. (*p < 0.05 and **p < 0.01). LXA4, lipoxin A4; RvE1, resolvin E1
FIGURE 6
FIGURE 6
(A) Representative immunohistochemistry‐stained images of NLRP3, caspase‐1, IL‐1β, and IL‐18 of day 3 samples. (B) Isotype control. Statistical analysis of (C) NLRP3‐, (D) caspase‐1‐, (E) IL‐1β‐ and (F) IL‐18‐positive cells. (*p < 0.05 and **p < 0.01)
FIGURE 7
FIGURE 7
The molecular mechanism by which the RvE1 and LXA4 combination resolves pulpitis as proposed in the present study. LXA4, lipoxin A4; RvE1, resolvin E1

References

    1. Bai J, Xu T, Ji AP, Sun W, Huang MW. Impact of COVID‐19 on oral emergency services. Int Dent J. 2021;71:27‐31. - PMC - PubMed
    1. Salgarello S, Salvadori M, Mazzoleni F, et al. Urgent dental care during Italian lockdown: a cross‐sectional survey. J Endod. 2021;47:204‐214. - PubMed
    1. Cushley S, Duncan HF, Lappin MJ, et al. Efficacy of direct pulp capping for management of cariously exposed pulps in permanent teeth: a systematic review and meta‐analysis. Int Endod J. 2021;54:556‐571. - PubMed
    1. Arora S, Cooper PR, Friedlander LT, et al. Potential application of immunotherapy for modulation of pulp inflammation: opportunities for vital pulp treatment. Int Endod J. 2021;54:1263‐1274. - PubMed
    1. Liu X, Zhang W, Wang Y, et al. One‐step treatment of periodontitis based on a core‐shell micelle‐in‐nanofiber membrane with time‐programmed drug release. J Control Release. 2020;320:201‐213. - PubMed